.

Rejuvenate Biomed: Positive results

Diepenbeek, Belgium, October 4, 2023 – Rejuvenate Biomed NV ("Rejuvenate Biomed"), a clinical-stage company dedicated to advancing therapeutics to delay the onset of age-related diseases, today announced the successful completion of a 6-week clinical proof-of-mechanism study with lead candidate RJx-01. RJx-01, a novel combination drug comprising galantamine and metformin, demonstrated positive results in 42 elderly male subjects with disuse-induced muscle atrophy.

CatalYm in Nature Communications

Munich, Germany, July 20, 2023 – CatalYm today announced the publication of preclinical data in Nature Communications under the title "Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment". The study reveals a central role of GDF-15 in the resistance of tumors to current immunotherapy.

OncoDNA: Closing Round C financing

July 3, 2023 – OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, today announced the closing of a Round C financing of 6,5 M€, entirely subscribed by its current shareholders.

Memo Therapeutics: U.S. Pivotal Phase II/III

Schlieren/Zurich, Switzerland, June 22, 2023 – Memo Therapeutics AG ("MTx") announced today that the first patient has been enrolled in a pivotal, multicenter U.S. Phase II/III trial of AntiBKV, MTx's antibody therapeutic that targets BK polyomavirus ("BKV") infection in renal transplant patients. MTx recently received Fast Track designation for AntiBKV from the U.S. Food and Drug Administration ("FDA").

CatalYm Announces Initial Data

Munich, Germany, June 6, 2023 – CatalYm today announced first Phase 2a data from its ongoing GDFather-2 trial (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 2) (NCT04725474) at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023 in Chicago, Illinois. The early data presented during today's oral "Developmental Therapeutics-Immunotherapy" session revealed lasting and confirmed responses in several solid tumor types investigated following treatment with visugromab and the anti-PD-1 inhibitor nivolumab.

Topas Initiates Phase 2a Clinical Trial

Hamburg, Germany, May 25, 2023 – Topas Therapeutics, a clinical stage biotech company developing novel antigen-specific immune tolerance therapies to treat autoimmune disorders, announced today the launch of a Phase 2a clinical study (NCT05660109) evaluating the safety, tolerability and pharmacodynamics of TPM502 in patients with celiac disease.

Memo Therapeutics: FDA Designation

Schlieren/Zurich, Switzerland – May 2, 2023 – Memo Therapeutics AG ("MTx") announced today that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation to AntiBKV, MTx's lead antibody therapeutic that targets BK polyomavirus ("BKV") infection commonly seen in renal transplant patients.

Memo Therapeutics: Positive Phase I Data

Schlieren/Zurich, Switzerland – January 24, 2023 – Memo Therapeutics AG ("MTx"), an innovator in the field of antibody discovery and development, announced today positive safety and tolerability data from a Phase I clinical trial with AntiBKV, an antibody targeting BK polyomavirus ("BKV") infection in renal transplant patients, meeting its primary endpoint.

CatalYm: Visugromab Development

Munich, Germany, December 14, 2022 – CatalYm today announced three major expansions of its ongoing Phase 2 visugromab clinical development program. Based on initial positive patient responses, the company is advancing two potential lead indication cohorts into the second stage of the Simon-2-stage design ahead of schedule.

CatalYm: EUR 50 Million Financing

Munich, Germany, November 22, 2022 – CatalYm today announced the close of a EUR 50 million (USD 49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation from existing investors Forbion, Novartis Venture Fund, Vesalius Biocapital III, Bayern Kapital, BioGeneration Ventures and Coparion.

.

xxnoxx_zaehler